Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial.

Contemp Clin Trials Commun · 2020 · PMC7025084 · PMID 32083220

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Finally, the bladder preservation for patients with complete clinical response after NAC is not recommended currently, but the pathologic downstaging (pT1 N0M0) and the rate of pathologic complete response (pT0) may be significant prognostic factors in NAC response.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.